AstraZeneca Sees Emerging Market Opportunity for Forest Anti-Infective

AstraZeneca's deal for Forest's Phase III ceftaroline may be ex-U.S., Canada and Japan, but it grants the Big Pharma rights in key emerging markets including China, and fills a late-stage pipeline gap.